Current Report Filing (8-k)
May 19 2016 - 11:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
May 19, 2016 (May 16, 2016)
IMPLANT SCIENCES CORPORATION
(Exact name of Registrant as Specified in its Charter)
MASSACHUSETTS
(State or Other Jurisdiction of Incorporation)
|
| |
001-14949
|
|
04-2837126
|
(Commission File Number)
|
|
(I.R.S. Employer Identification Number)
|
500 Research Drive, Unit 3
Wilmington, Massachusetts 01887
(Address of Principal Executive Offices, including Zip Code)
(978) 752-1700
(Registrants Telephone Number, including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
□
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02
Results of Operations and Financial Condition
On May 16, 2016, the Company issued a press release announcing its financial results for the quarter ended March 31, 2016.
Item 7.01
Regulation FD Disclosure
On May 16, 2016, the Company issued the press release described in Item 2.02 above. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.
Item 8.01 Other Events
On May 16, 2016, the Company held a telephonic conference call to discuss the Companys financial results for the quarter ended March 31, 2016. A copy of the transcript of the conference call is attached hereto as Exhibit 99.2 and is incorporated herein by this reference.
The press release and the Companys conference call script furnished under Item 7.01 and 8.01, including Exhibits 99.1and 99.2, of this Form 8-K shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall they be deemed incorporated by reference in any filing under the Securities Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits
Exhibit No.
Description
99.1
Press Release of Implant Sciences Corporation, dated May 16, 2016.
99.2
Implant Sciences Corporation conference call transcript held on May 16, 2016
at 4:15 PM ET.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMPLANT SCIENCES CORPORATION
By: /
s/ Roger P. Deschenes
Roger P. Deschenes
Vice President, Finance and Chief Financial Officer
Date: May 19, 2016
3
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release of Implant Sciences Corporation, dated May 16, 2016.
99.2
Transcript of Implant Sciences Corporation conference call held on May 16, 2016
at 4:15 PM ET.